Reduction in Balloon Pump Size Reduces Axillary Intraaortic Balloon Pump Failure Risk.
Sara S InglisArdaas KanwarHilda Gonzalez BonillaSwaiman SinghJennifer Y PearsonMohsin AbbasLori A FolkensNarith N OuPhilip J SpencerMauricio A VillavicencioAlfredo L ClavellRobert P FrantzAndrew N RosenbaumAtta BehfarPublished in: ASAIO journal (American Society for Artificial Internal Organs : 1992) (2024)
Axillary artery intra-aortic balloon pump (axIABP) placement has been implemented as a bridging solution before heart transplantation. This study evaluates complications associated with axIABP support and describes an approach to minimize adverse events. We previously described a percutaneous approach for axIABP placement. However, patients receiving axIABP between September 1, 2017, and September 26, 2019 (n = 32) demonstrated a high rate of balloon pump malfunction (8/32; 25%) and other complications (totaling 15/32; 47%). Sixty-four patients were sequentially treated under a revised protocol. Compared to the initial cohort, no significant differences in demographics were noted. A significant reduction in rate of balloon malfunction (8/32, 25% vs. 1/64, 2%; p < 0.001) and total complications (15/32, 47% vs. 10/64, 16%; p = 0.0025) during the period of support were noted after intervention. Subsequent analysis of total complications per device size (40 vs. ≤ 34 ml balloon) revealed significantly reduced complications in patients with smaller devices (40% vs. 13%, respectively; p = 0.0022). This study provides guidelines to limit complications in patients supported with axIABP, facilitating a protracted period of bridging support.
Keyphrases
- end stage renal disease
- risk factors
- newly diagnosed
- ultrasound guided
- ejection fraction
- randomized controlled trial
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- heart failure
- left ventricular
- clinical practice
- single cell
- radiation therapy
- aortic valve
- early stage
- sentinel lymph node
- pulmonary artery
- rectal cancer
- radiofrequency ablation